Urology
Volume 73, Issue 5, Supplement , Pages S1-S3 , May 2009

Introduction

  • Gerald L. Andriole

      Affiliations

    • Corresponding Author InformationReprint requests: Gerald L. Andriole, M.D., Division of Urology, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, Siteman Cancer Center, 4960 Children's Place, Campus Box 8242, St. Louis, MO 63110

Received 2 February 2009 ,Accepted 21 February 2009.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Ries L, Melbert D, Drapcho M, et al. SEER cancer statistics review (based on November 2007 SEER data submission, posted to SEER Web site). http://seer.cancer.gov/csr/1975_2005/2008;Accessed May 30, 2008
  3. National Cancer Institute. Cancer trends progress report. http://cancercontrolplanet.cancer.gov/atlas/progressreport/alacarte/ctpr_2007_report.jspAccessed November 20, 2008
  4. Tindall DJ, Rittmaster RS. The rationale for inhibiting 5α-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol. 2008;179:1235–1242
  5. Loeb S, Catalona WJ. What to do with an abnormal PSA test. Oncologist. 2008;13:299–305
  6. Schröder FH, Roobol MJ, Andriole GL, et al. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol. 2009;181:69–74
  7. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. Can Med Assoc J. 2007;176:1853–1858
  8. Lilja H, Ulmert D, Björk T, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44-50 years. J Clin Oncol. 2007;25:431–436
  9. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268–278
  10. Ulmert D, Cronin AM, Bjork T, et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med. 2008;6:6
  11. Fang J, Metter EJ, Landis P, et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology. 2001;58:411–416
  12. Kumar RJ, Barqawi A, Crawford ED. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol. 2005;7(suppl 5):S37–S43
  13. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261
  14. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  15. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol. 2004;172(4 Pt. 1):1314–1317

 G. L. Andriole serves as a consultant to Aeterna Zentaris, Nema Steba, Onconome, and GlaxoSmithKline and has received research funding from Envisioneering, Ferring Pharmaceuticals, GlaxoSmithKline, Veridex, Viking Medical, and Zeneca.

 Editorial support and funding for medical writing assistance by IntraMed provided by GlaxoSmithKline.

PII: S0090-4295(09)00273-8

doi: 10.1016/j.urology.2009.02.021

Urology
Volume 73, Issue 5, Supplement , Pages S1-S3 , May 2009

Article Tools